Fever News and Research

RSS

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

OSU microbiologists discover new type of dairy or food thickener with probiotic characteristics

Microbiologists at Oregon State University have discovered and helped patent and commercialize a new type of dairy or food thickener, which may add probiotic characteristics to the products in which it's used.

10 Jun 2015

Danish nasal filter prevents pollen inhalation, reduces symptoms of hay fever

Getting through the pollen season can now become easier for some of the approximately 500 million people worldwide who suffer from sneezing and a runny nose, watery eyes and drowsiness during the allergy season (seasonal allergic rhinitis).

10 Jun 2015

Researchers develop device to diagnose bacterial meningitis in babies

Currently the only test to diagnose bacterial meningitis in babies is through a lumbar puncture, a painful and difficult procedure to perform. For this reason, a group of biomedical engineers decided to search for an alternative and developed a portable device that can detect this illness with a simple ultrasound scan of the fontanelle.

9 Jun 2015

Designing infectious disease forecasting models to predict dengue epidemics

Dengue viruses are on the move. Spread among humans by mosquitoes, and across geographic boundaries through travel, the virus affects up to an estimated 390 million people every year around the world. In the U.S., recent outbreaks have occurred in Florida, Texas, Hawaii, and Puerto Rico. Scientists know one of the best ways to reduce the impact of the disease is to prepare healthcare providers by forecasting epidemics before they happen.

8 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Researchers at the University of Bonn and the German Center for Infection Research (DZIF) have discovered two new groups of viruses within the Bunyavirus family in the tropical forest of Ivory Coast. Previously only five groups responsible for serious illnesses in humans and animals were known.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience.

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Pennsylvania confirms first 2015 detections of West Nile Virus from mosquito sample

The Pennsylvania Departments of Environmental Protection and Health are reporting the confirmation of the first 2015 detections of West Nile Virus from a mosquito sample that was collected on May 22 in Springettsbury Township, York County and a bird found May 26 in Harris Township, Centre County.

30 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Fever News and Research

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

OSU microbiologists discover new type of dairy or food thickener with probiotic characteristics

Danish nasal filter prevents pollen inhalation, reduces symptoms of hay fever

Researchers develop device to diagnose bacterial meningitis in babies

Designing infectious disease forecasting models to predict dengue epidemics

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Pennsylvania confirms first 2015 detections of West Nile Virus from mosquito sample

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News